Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defectsEffects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin
Chretien P, Lipson S, Makuch R, Kenady D, Snyder J, Cohen M. Effects of Thymosin Fraction 5 in Cancer Patients: In Vitro Studies and Correlations with Clinical Course in Patients Receiving Thymosin. 1979, 159-166. DOI: 10.1016/b978-0-08-023194-5.50023-1.Peer-Reviewed Original ResearchT cell levelsThymosin fraction 5Cancer patientsClinical coursePatient groupT cellsLow CEA levelWeeks of therapyCell-mediated immunityEffect of thymosinSmall cell carcinomaSuch patient groupsComplete tumor remissionFraction 5Certain serum glycoproteinsSimilar groupsAdjuvant treatmentIntensive chemotherapyImmunologic effectsCEA levelsFurther therapyImmune defectsCellular immunityCell carcinomaTumor remission